Invasive lobular breast carcinoma – Basic Information

Go back

Invasive lobular breast carcinoma is a type of breast cancer that begins in the milk-producing glands of the breast and spreads into surrounding tissue. Unlike other breast cancers, it often grows in subtle ways that can make it harder to detect, yet understanding its unique characteristics is essential for anyone seeking to recognize potential warning signs and navigate treatment options.

Understanding Invasive Lobular Breast Carcinoma

Invasive lobular breast carcinoma, also called invasive lobular carcinoma or ILC, starts in the lobules, which are the small, rounded structures in the breast that produce milk during breastfeeding. The word “invasive” means the cancer cells have broken out from where they first appeared and have moved into the surrounding breast tissue. From there, these cells have the potential to travel to lymph nodes and other parts of the body.[1]

This form of breast cancer is distinct from the more common invasive ductal carcinoma, which begins in the milk ducts rather than the lobules. The location where cancer originates matters because it influences how the disease behaves, how it appears on imaging tests, and sometimes how it responds to treatment.[2]

What makes invasive lobular carcinoma particularly unique is the way its cells grow. Instead of clustering together to form a noticeable lump, ILC cells tend to spread out in single-file lines or strands throughout the breast tissue. This unusual growth pattern is due to the loss of a protein called E-cadherin, which normally helps cells stick together. Without this protein, cancer cells move independently through tissue, creating a diffuse pattern rather than a solid mass.[15]

How Common Is This Disease

Invasive lobular carcinoma accounts for approximately ten to fifteen percent of all invasive breast cancers, making it the second most common type after invasive ductal carcinoma. Despite being labeled as less common, ILC affects tens of thousands of women each year. In the United States alone, an estimated 43,000 to 47,500 new cases are diagnosed annually.[2][5]

Over the past two decades, the number of invasive lobular carcinoma cases has been rising. Researchers have observed this increase across different populations, though the reasons behind this trend are not entirely clear. Some experts believe improved detection methods and greater awareness among healthcare providers may be contributing factors.[2]

ILC tends to affect women who are slightly older than those diagnosed with other breast cancer types. The average age at diagnosis is about three years higher compared to invasive ductal carcinoma. Approximately sixty-eight percent of all new lobular diagnoses occur in women over the age of sixty, while fifty-nine percent of non-lobular breast cancer diagnoses happen in this age group.[5][9]

When looking at racial and ethnic patterns, invasive lobular carcinoma shows some variation. Among newly diagnosed cases in the United States, seventy-three percent occur in non-Hispanic white women, nine percent in non-Hispanic Black women, five percent in non-Hispanic Asian or Pacific Islander women, and twelve percent in Hispanic women of all races. This distribution differs somewhat from other breast cancer types, suggesting biological or environmental factors may influence who develops this particular form of the disease.[5]

Breast cancer in general is extremely rare in men, and invasive lobular carcinoma is even more unusual in male patients. When men do develop breast cancer, it is very uncommon for it to be the lobular type.[7]

What Causes Invasive Lobular Carcinoma

Like many cancers, invasive lobular carcinoma develops when genetic changes, called mutations, cause normal cells to transform into cancer cells. These mutations alter the instructions that tell cells how to grow, divide, and die. When these controls break down, cells can multiply uncontrollably and spread to areas where they don’t belong.[3]

Scientists have identified specific molecular changes that are particularly important in the development of lobular breast cancer. The most significant involves a gene called CDH1, which provides instructions for making E-cadherin, the protein that helps cells adhere to one another. When this gene is inactivated through mutations or other mechanisms, cells lose their ability to stick together. This loss of cell-to-cell adhesion is a hallmark feature of ILC and explains why these tumors grow in scattered lines rather than forming distinct lumps.[9][15]

Researchers have also found that genes involved in a cellular pathway called the phosphatidylinositol 3-kinase pathway, particularly a gene named PIK3CA, play important roles in lobular breast cancer development. These discoveries are helping scientists understand why ILC behaves differently from other breast cancers.[9]

While genetic changes within breast cells are the immediate cause of cancer, the deeper question of what triggers these mutations in the first place remains largely unanswered. Experts believe a combination of inherited genetic factors and environmental exposures likely contribute, but the exact causes are still not fully understood.[3]

Risk Factors for Developing This Cancer

Several factors can increase a woman’s likelihood of developing invasive lobular carcinoma. Understanding these risk factors can help individuals and their healthcare providers make informed decisions about screening and prevention strategies.

Age is one of the strongest risk factors. Being fifty-five years old or older significantly increases the chances of developing ILC. As women get older, their cumulative exposure to various biological and environmental factors grows, and their cells have had more time to accumulate potentially harmful genetic changes.[3]

Reproductive history also plays a role. Women who gave birth after age thirty or who never gave birth face higher risk. Similarly, starting menstruation before age twelve or entering menopause after age fifty-five extends the number of years a woman’s breast tissue is exposed to hormones, particularly estrogen, which can influence cancer development.[3]

Hormone replacement therapy for managing menopause symptoms has been linked to increased risk of invasive lobular carcinoma. Certain types of hormone therapy appear to carry higher risk than others, and the duration of use matters. Women who use these therapies should discuss the potential benefits and risks with their healthcare providers.[3]

Having a personal history of breast cancer or a condition called lobular carcinoma in situ, or LCIS, increases risk. LCIS itself is not cancer, but its presence indicates abnormal cell growth in the lobules and serves as a marker for elevated breast cancer risk in the future.[3]

Family history matters considerably. Women with close relatives who have had breast cancer or ovarian cancer face higher risk, especially if multiple family members were affected or if cancer occurred at young ages. In some families, inherited genetic mutations such as changes in BRCA1, BRCA2, or other genes substantially increase breast cancer risk, though these hereditary factors account for a minority of all cases.[3]

⚠️ Important
Having one or more risk factors does not mean a woman will definitely develop invasive lobular carcinoma. Many women with risk factors never develop breast cancer, while some women without apparent risk factors do. Risk factors help identify who might benefit from closer monitoring or preventive measures, but they cannot predict individual outcomes with certainty.

Recognizing the Symptoms

The symptoms of invasive lobular carcinoma can be subtle and may differ from what many people expect when they think of breast cancer. Because ILC cells grow in scattered patterns rather than forming firm masses, this cancer often does not create the distinct lump that other breast cancers typically produce. This characteristic can make it harder to detect through self-examination or even during clinical breast exams.[1]

In its early stages, invasive lobular carcinoma may cause no noticeable signs or symptoms at all. As the cancer grows larger, however, women may begin to experience changes in their breasts. One common symptom is an area of thickening in the breast tissue. Rather than feeling like a hard, round lump, the affected area might feel more like a region where the tissue has become denser or firmer than the surrounding breast.[1][7]

Some women notice a new area of fullness or swelling in the breast. This might appear as a change in breast size or shape, or as one breast looking different from the other. The breast may feel heavier on one side, or there might be an area that seems to bulge or protrude slightly.[1]

Changes to the skin over the breast can also signal invasive lobular carcinoma. The skin might develop dimpling, which looks like small indentations similar to the surface of an orange peel. Some women notice areas where the skin appears thicker than normal or where it has changed texture. These skin changes occur because cancer growing beneath the surface can pull on or infiltrate the overlying tissue.[1][7]

Nipple changes are another possible symptom. A nipple that previously pointed outward might turn inward, a condition called inversion. Some women experience discharge from the nipple, which may be clear or bloody. The nipple area might also become red or develop a rash-like appearance.[1][3]

In some cases, women may feel breast pain or notice warmth in part of the breast. The skin might become discolored, appearing reddish or darker than usual. A lump near the armpit can develop if cancer has spread to the lymph nodes in that area.[3]

It’s important to note that many of these symptoms can be caused by conditions other than cancer. Breast tissue naturally changes throughout a woman’s menstrual cycle, and benign conditions can cause lumps, thickening, or pain. However, any persistent change in the breast warrants medical evaluation. Women who notice any of these symptoms should contact their healthcare provider promptly, even if the changes seem minor or if a recent mammogram was normal.[1]

Prevention Strategies

While there is no guaranteed way to prevent invasive lobular carcinoma or any breast cancer, certain strategies may help reduce risk. These approaches focus on modifying lifestyle factors that have been associated with breast cancer development.

Maintaining a healthy body weight through balanced nutrition and regular physical activity may help lower breast cancer risk. Being overweight or obese, particularly after menopause, has been linked to increased risk because fat tissue produces estrogen, and higher estrogen levels over time can contribute to cancer development. A diet rich in fruits, vegetables, whole grains, and lean proteins, while limiting processed foods and red meat, supports overall health and may offer some protective benefits.[4]

Limiting alcohol consumption is another important consideration. Research has shown that drinking alcohol increases breast cancer risk, and the risk rises with the amount consumed. Women who choose to drink should do so in moderation, which generally means no more than one drink per day.[4]

Breastfeeding, if possible, may provide some protection against breast cancer. Women who breastfeed for longer periods appear to have slightly lower risk compared to those who never breastfeed or do so only briefly. The biological mechanisms behind this protective effect may relate to the way breastfeeding affects hormone levels and breast tissue development.[4]

Being cautious about hormone replacement therapy is advisable. Women considering hormone therapy to manage menopause symptoms should discuss the potential risks and benefits thoroughly with their healthcare providers. If hormone therapy is necessary, using the lowest effective dose for the shortest time needed may help minimize risk. Some types of hormone therapy carry higher risk than others, and alternatives may be available for managing menopause symptoms.[4]

For women at very high risk due to strong family history or genetic mutations, more intensive prevention strategies may be appropriate. These can include preventive medications, more frequent or advanced screening methods, or in some cases, preventive surgery. Such decisions are highly personal and should be made in close consultation with healthcare providers who specialize in cancer genetics and risk assessment.

Regular screening through mammography and clinical breast exams plays a crucial role in early detection rather than prevention. Most healthcare professionals recommend that women begin discussing breast cancer screening with their providers starting in their forties, though recommendations may vary based on individual risk factors. Early detection allows for treatment when cancer is most manageable, which significantly improves outcomes.[1]

How the Disease Affects the Body

Understanding how invasive lobular carcinoma develops and spreads requires looking at what happens at the cellular and tissue level. In healthy breast tissue, cells grow, divide, and die in an orderly, controlled manner. They communicate with neighboring cells and respond to signals that tell them when to stop growing. Normal lobular cells maintain their shape and position because they’re held together by adhesion proteins like E-cadherin.[15]

In invasive lobular carcinoma, the loss of E-cadherin function fundamentally changes how cells behave. Without this adhesive protein, individual cancer cells can slip away from their original location and move through breast tissue more easily. Rather than forming a cohesive mass, they infiltrate the surrounding tissue in characteristic single-file lines or chain-like patterns. Pathologists can recognize this distinctive arrangement when they examine tissue samples under a microscope.[9][15]

This diffuse growth pattern has several consequences. It can make the cancer harder to feel during a breast exam because there may not be a discrete lump. It also means that invasive lobular carcinoma can spread through a larger area of breast tissue than might be apparent from initial examinations. Sometimes multiple areas within the breast are involved simultaneously, a pattern called multicentric disease. ILC is more likely than other breast cancers to affect both breasts, either at the same time or years apart.[12][20]

Most invasive lobular carcinomas are driven by hormones. The cancer cells typically have receptors on their surfaces that bind to estrogen and progesterone. When these hormones attach to their receptors, they signal the cancer cells to grow and multiply. This characteristic makes the cancer responsive to hormone-blocking therapies. The majority of ILC cases are also HER2-negative, meaning they don’t have excessive amounts of a protein called human epidermal growth factor receptor 2.[15][20]

As invasive lobular carcinoma progresses, cancer cells can enter the lymphatic system or bloodstream. The lymph nodes under the arm are often the first place outside the breast where cancer spreads. From there, cancer cells can travel to distant organs. When this happens, the disease is called metastatic breast cancer.[1]

One notable feature of invasive lobular carcinoma is its pattern of metastasis. While breast cancer commonly spreads to bones, lungs, liver, and brain, ILC has an unusual tendency to metastasize to less common sites. Cancer cells can spread to the gastrointestinal tract, including the stomach, small intestine, and colon. They may also reach the peritoneum (the lining of the abdominal cavity), the reproductive organs such as the ovaries and uterus, or even the tissues around the eyes. The cancer can affect the lining of the brain and spinal cord in a pattern called leptomeningeal spread.[3][6]

⚠️ Important
Invasive lobular carcinoma can recur many years after initial diagnosis and treatment. Some women experience metastatic disease ten to fifteen years after their original treatment, even when their initial cancer appeared to be successfully treated. This long potential delay emphasizes the importance of continued follow-up care and remaining alert to new symptoms throughout survivorship.

Because of these unusual spread patterns, invasive lobular carcinoma can cause a wide range of symptoms depending on where it metastasizes. Gastrointestinal involvement might cause symptoms that mimic other digestive conditions, such as nausea, changes in bowel habits, or abdominal discomfort. This can sometimes delay diagnosis of metastatic disease because symptoms may not immediately suggest breast cancer recurrence. Healthcare providers caring for women with a history of ILC need to maintain awareness of these unusual metastatic patterns when evaluating new health complaints.[6]

Ongoing Clinical Trials on Invasive lobular breast carcinoma

  • Study of Capivasertib and Fulvestrant for Patients with High-Risk Lobular Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

References

https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/symptoms-causes/syc-20373973

https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

https://my.clevelandclinic.org/health/diseases/21180-lobular-breast-cancer

https://www.nationalbreastcancer.org/invasive-lobular-carcinoma/

https://seer.cancer.gov/statfacts/html/ilc.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC4289705/

https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/invasive-lobular-breast-cancer

https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/diagnosis-treatment/drc-20373979

https://www.ncbi.nlm.nih.gov/books/NBK554578/

https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

https://www.nationalbreastcancer.org/invasive-lobular-carcinoma/

https://www.dana-farber.org/cancer-care/treatment/breast-oncology/programs/invasive-lobular-breast-cancer

https://www.melbournebreastcancersurgery.com.au/breast-cancer/invasive-lobular-cancer-ilc.html

https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/invasive-lobular-breast-cancer

https://lobularbreastcancer.org/faq/

https://www.nationalbreastcancer.org/invasive-lobular-carcinoma/

https://www.mayoclinic.org/diseases-conditions/invasive-lobular-carcinoma/diagnosis-treatment/drc-20373979

https://lobularbreastcancer.org/my-ilc-story-lucy/

https://www.bcrf.org/about-breast-cancer/invasive-lobular-carcinoma/

https://www.komen.org/breast-cancer/diagnosis/invasive-lobular-breast-cancer/

https://www.youtube.com/watch?v=gtZtG4Y6hxI

https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/invasive-lobular-breast-cancer

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

https://www.roche.com/stories/terminology-in-diagnostics

FAQ

Can a mammogram miss invasive lobular carcinoma?

Yes, invasive lobular carcinoma is more likely to be missed on mammograms compared to other breast cancers. Because ILC cells grow in scattered lines rather than forming dense masses, they may not show up as clearly on X-ray images. Additional imaging tests such as breast ultrasound or MRI may be needed, especially in women with dense breast tissue.

Is invasive lobular carcinoma more aggressive than other breast cancers?

Invasive lobular carcinoma typically grows more slowly than the most common type of breast cancer (invasive ductal carcinoma) and tends to have a lower grade at diagnosis. However, it often presents at a larger size and has unique spreading patterns. The cancer’s behavior depends on many factors including stage, hormone receptor status, and individual characteristics.

What is the difference between lobular carcinoma in situ (LCIS) and invasive lobular carcinoma?

These are two completely different conditions. Lobular carcinoma in situ (LCIS) is not cancer but rather abnormal cells confined to the lobules that serve as a marker for increased breast cancer risk in the future. Invasive lobular carcinoma (ILC) is actual cancer where cells have broken out of the lobules and spread into surrounding breast tissue, with potential to travel to other parts of the body.

Does invasive lobular carcinoma affect both breasts more often than other breast cancers?

Yes, invasive lobular carcinoma is more likely to occur in both breasts (bilateral disease) compared to invasive ductal carcinoma. Studies show that about twenty percent of women with bilateral breast cancer at diagnosis have ILC. This increased risk of bilateral disease is one reason why careful examination of both breasts is important during diagnosis and follow-up.

If I had invasive lobular carcinoma years ago and finished treatment, should I still be concerned about recurrence?

Yes, continued monitoring remains important even many years after treatment. One unique feature of invasive lobular carcinoma is that it can recur or metastasize ten to fifteen years after the original diagnosis and successful treatment. Regular follow-up appointments with your healthcare team and promptly reporting any new symptoms are essential throughout survivorship.

🎯 Key takeaways

  • Invasive lobular carcinoma is the second most common type of breast cancer, affecting approximately 43,000 to 47,500 women in the United States each year.
  • Unlike other breast cancers, ILC grows in single-file lines rather than forming lumps, making it harder to detect on mammograms and through self-examination.
  • The loss of a protein called E-cadherin causes ILC cells to lose their ability to stick together, explaining their unique spreading pattern.
  • ILC tends to affect older women, with sixty-eight percent of cases diagnosed in women over age sixty.
  • This cancer can spread to unusual locations including the stomach, intestines, reproductive organs, and the lining around the brain and spinal cord.
  • Invasive lobular carcinoma can recur or metastasize many years—sometimes ten to fifteen years—after initial treatment, making long-term follow-up essential.
  • Risk factors include being over fifty-five, having a family history of breast cancer, using certain hormone replacement therapies, and having reproductive factors like late childbirth.
  • Most ILC cases are hormone receptor-positive and HER2-negative, meaning they respond to hormone-blocking treatments but not HER2-targeted therapies.

Connected medications: